secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001104659-24-061579
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acurx Pharma Q1 net loss $4.4M; Phase 2b data positive, FDA agrees on Phase 3 plan
--------------------------------------------------------------------------------

- Net loss of $4.4M ($0.28/diluted share) vs $2.9M loss in Q1 2023; R&D expenses $1.6M, G&A $2.8M.
- Cash $8.9M at March 31, 2024; raised ~$4.4M gross via ATM sale of 1,121,793 shares in Q1.
- Phase 2b ibezapolstat results: 94% eradication of fecal C. difficile at Day 3 vs 71% for vancomycin; preserved gut microbiome.
- End of Phase 2 meeting with FDA in April 2024; agreement reached on Phase 3 program and NDA pathway.
- EMA approved SME designation for Acurx, granting fee reductions and support for European marketing authorization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465924061579/0001104659-24-061579-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465924061579/tm2414469d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-061579

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer